Detailed Information for S00117

Basic information about inhibitors

IPAD-DB ID S00117
Name 16-Deoxo-paraherquamide
Category Synthetic compounds
2D Structure
3D Structure
Molecular Formula C 2 8 H 3 5 N 3 O 4
Molecular Weight 477.6g/mol
IUPAC Name  (1'S, 5'R, 7'S, 8R, 9'S)-4, 4, 5', 10', 10', 13'-hexamethylspiro[10H-[1, 4]dioxepino[2, 3-g]indole-8, 11'-3, 13-diazatetracyclo[5.5.2.01, 9.03, 7]tetradecane]-9, 14'-dione 
InChI InChI=1S/C28H35N3O4/c1-16-11-26-12-19-25(4, 5)28(14-27(19, 15-31(26)13-16)30(6)23(26)33)17-7-8-18-21(20(17)29-22(28)32)34-10-9-24(2, 3)35-18/h7-10, 16, 19H, 11-15H2, 1-6H3, (H, 29, 32)/t16-, 19+, 26+, 27-, 28-/m1/s1
InChIKey UCHMXMCBFDOYNC-HTEKFMMOSA-N
Canonical SMILES CC1CC23CC4C(C5(CC4(CN2C1)N(C3=O)C)C6=C(C7=C(C=C6)OC(C=CO7)(C)C)NC5=O)(C)C
PubChem CID 127037732
DrugBank Accession Number -
CAS Registry Number -

Biological activity data

Ki -
EC50
IC50 269.5 μM(Aβ aggregation)
Inhibition
Toxicity
ROS(reactive oxygen species)
Metal Chelating
BBB(blood-brain barrier)
Target Protein
Effects Inhibit Aβ aggregation
Research Models In PC12 cell, in vitro
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME) 477.6
Hac(Computed by SwissADME) 35
Volume(Computed by ADMETlab 2.0) 485.281
Density(Computed by ADMETlab 2.0) 0.983
nRing(Computed by ADMETlab 2.0) 8
MaxRing(Computed by ADMETlab 2.0) 14
nHet(Computed by ADMETlab 2.0) 7
fChar(Computed by ADMETlab 2.0) 0
nRig(Computed by ADMETlab 2.0) 35
Flexibility(Computed by ADMETlab 2.0) 0
Stero Centers(Computed by ADMETlab 2.0) 6
LogS(Computed by ADMETlab 2.0) -5.093
LogD(Computed by ADMETlab 2.0) 3.251

ADMET properties

logP(Computed by ADMETlab 2.0) 4.488
TPSA(Computed by SwissADME) 71.11
Hbond Acceptor(Computed by SwissADME) 5
Hbond Donor(Computed by SwissADME) 1
Rotatable Bonds(Computed by SwissADME) 0

Pharmacokinetics

GI Absorption(Computed by SwissADME) High
BBB(blood-brain barrier) Permeant(Computed by SwissADME) Yes
P-gp Substrate(Computed by SwissADME) No
CYP1A2 Inhibitor(Computed by SwissADME) No
CYP2C19 Inhibitor(Computed by SwissADME) No
CYP2C9 Inhibitor(Computed by SwissADME) No
CYP2D6 Inhibitor(Computed by SwissADME) No
CYP3A4 Inhibitor(Computed by SwissADME) No
log Kp(Skin Permeation)(Computed by SwissADME) -7.17

Druglikeness

Lipinski(Computed by SwissADME) 0
Ghose(Computed by SwissADME) 1
Veber(Computed by SwissADME) 0
Egan(Computed by SwissADME) 0
Muegge(Computed by SwissADME) 0
Bioavailability Score(Computed by SwissADME) 0.55